Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study

Molecular Oncology

Volumn 9, Issue 1, 2015, Pages 128-139

  Tenori, Leonardo ^a,b   Oakman, Catherine ^c   Morris, Patrick G ^d   Gralka, Ewa ^a,b   Turner, Natalie ^c   Cappadona, Silvia ^c   Fornier, Monica ^d   Hudis, Cliff ^d   Norton, Larry ^d   Luchinat, Claudio ^a   Di Leo, Angelo ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b FiorGen Foundation   (Italy)

^c ISTITUTO TOSCANO TUMORI   (Italy)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Biomarker; Breast cancer; Metabolites; Metabolomics; Micrometastases; Nuclear magnetic resonance spectroscopy

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; GLUCOSE; HISTIDINE; LACTIC ACID; LIPID; TRASTUZUMAB; TYROSINE;

ACCURACY; ADJUVANT THERAPY; ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BREAST CANCER; BREAST METASTASIS; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; EARLY CANCER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LACTATE BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLOMICS; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOM FOREST; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SERUM; BIOLOGICAL MODEL; BLOOD; BREAST NEOPLASMS; CLINICAL TRIAL; METABOLOME; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; PROGNOSIS; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; METABOLOME; METABOLOMICS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES;

EID: 84920627016     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.07.012     Document Type: Article

References (36)

1. Aboagye E.O., Bhujwalla Z.M. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res. 1999, 59:80-84.
2. Aranibar N., Borys M., Mackin N.A., Ly V., Abu-Absi N., Abu-Absi S., Niemitz M., Schilling B., Li Z.J., Brock B., Russell R.J., Tymiak A., Reily M.D. NMR-based metabolomics of mammalian cell and tissue cultures. J.Biomol. NMR 2011, 49:195-206.
3. Asiago V.M., Alvarado L.Z., Shanaiah N., Gowda G.A., Owusu-Sarfo K., Ballas R.A., Raftery D. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010, 70:8309-8318.
4. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J.R. Stat. Soc. B 1995, 57:289-300.
5. Bertini I., Cacciatore S., Jensen B.V., Schou J.V., Johansen J.S., Kruhoffer M., Luchinat C., Nielsen D.L., Turano P. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res. 2012, 72:356-364.
6. Bollard M.E., Stanley E.G., Lindon J.C., Nicholson J.K., Holmes E. NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition. NMR Biomed. 2005, 18:143-162.
7. Bonadonna G., Moliterni A., Zambetti M., Daidone M.G., Pilotti S., Gianni L., Valagussa P. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005, 330:217.
8. Borgan E., Sitter B., Lingjaerde O.C., Johnsen H., Lundgren S., Bathen T.F., Sorlie T., Borresen-Dale A.L., Gribbestad I.S. Merging transcriptomics and metabolomics - advances in breast cancer profiling. BMC Cancer 2010, 10:628.
9. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., Schlimok G., Diel I.J., Gerber B., Gebauer G., Pierga J.Y., Marth C., Oruzio D., Wiedswang G., Solomayer E.F., Kundt G., Strobl B., Fehm T., Wong G.Y., Bliss J., Vincent-Salomon A., Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. N.Engl. J. Med. 2005, 353:793-802.
10. Breiman L. Random forests. Mach. Learn. 2001, 45:5-32.
11. Budczies J., Denkert C., Muller B.M., Brockmoller S.F., Klauschen F., Gyorffy B., Dietel M., Richter-Ehrenstein C., Marten U., Salek R.M., Griffin J.L., Hilvo M., Orešič M., Wohlgemuth G., Fiehn O. Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics study. BMC Genomics 2012, 13:334.
12. Cuadrado A., Carnero A., Dolfi F., Jimenez B., Lacal J.C. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 1993, 8:2959-2968.
13. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
14. Giskeodegard G.F., Lundgren S., Sitter B., Fjosne H.E., Postma G., Buydens L.M., Gribbestad I.S., Bathen T.F. Lactate and glycine-potential MR biomarkers of prognosis in estrogen receptor-positive breast cancers. NMR Biomed. 2012, 25:1271-1279.
15. Griffin J.L. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr. Opin. Chem. Biol. 2003, 7:648-654.
16. Griffin J.L., Shockcor J.P. Metabolic profiles of cancer cells. Nat. Rev. Cancer 2004, 4:551-561.
17. Holmes E., Foxall P.J., Nicholson J.K., Neild G.H., Brown S.M., Beddell C.R., Sweatman B.C., Rahr E., Lindon J.C., Spraul M., Neidig P. Automatic data reduction and pattern recognition methods for analysis of 1H nuclear magnetic resonance spectra of human urine from normal and pathological states. Anal. Biochem. 1994, 220:284-296.
18. Ihaka R., Gentleman R.R. A language for data analysis and graphics. J.Comput. Graph. Stat. 1996, 5:299-314.
19. Jobard E., Pontoizeau C., Blaise B.J., Bachelot T., Elena-Herrmann B., Tredan O. A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. Cancer Lett. 2014, 343:33-41.
20. Katz-Brull R., Seger D., Rivenson-Segal D., Rushkin E., Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res. 2002, 62:1966-1970.
21. Li M., Song Y., Cho N., Chang J.M., Koo H.R., Yi A., Kim H., Park S., Moon W.K. An HR-MAS MR metabolomics study on breast tissues obtained with core needle biopsy. PLoS ONE 2011, 6:e25563.
22. Liaw A., Wiener M. Classification and regression by randomForest. R.News 2002, 2:18-22.
23. Mackinnon W.B., Barry P.A., Malycha P.L., Gillett D.J., Russell P., Lean C.L., Doran S.T., Barraclough B.H., Bilous M., Mountford C.E. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer exvivo with proton MR spectroscopy. Radiology 1997, 204:661-666.
24. Mountford C.E., Somorjai R.L., Malycha P., Gluch L., Lean C., Russell P., Barraclough B., Gillett D., Himmelreich U., Dolenko B., Nikulin A.E., Smith I.C. Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine-needle aspirates analysed using a statistical classification strategy. Br. J. Surg. 2001, 88:1234-1240.
25. Nicholson J.K. Global systems biology, personalized medicine and molecular epidemiology. Mol. Syst. Biol. 2006, 2:52.
26. Oakman C., Tenori L., Claudino W.M., Cappadona S., Nepi S., Battaglia A., Bernini P., Zafarana E., Saccenti E., Fornier M., Morris P.G., Biganzoli L., Luchinat C., Bertini I., Di Leo A. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Ann. Oncol. 2011, 22:1295-1301.
27. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., Hiller W., Fisher E.R., Wickerham D.L., Bryant J., Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N.Engl. J. Med. 2004, 351:2817-2826.
28. Ravdin P.M., Siminoff L.A., Davis G.J., Mercer M.B., Hewlett J., Gerson N., Parker H.L. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J.Clin. Oncol. 2001, 19:980-991.
29. Serkova N.J., Niemann C.U. Pattern recognition and biomarker validation using quantitative 1H-NMR-based metabolomics. Expert Rev. Mol. Diagn. 2006, 6:717-731.
30. Singer S., Souza K., Thilly W.G. Pyruvate utilization, phosphocholine and adenosine triphosphate (ATP) are markers of human breast tumor progression: a 31P- and 13C-nuclear magnetic resonance (NMR) spectroscopy study. Cancer Res. 1995, 55:5140-5145.
31. Slupsky C.M., Steed H., Wells T.H., Dabbs K., Schepansky A., Capstick V., Faught W., Sawyer M.B. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin. Cancer Res. 2010, 16:5835-5841.
32. Spraul M., Neidig P., Klauck U., Kessler P., Holmes E., Nicholson J.K., Sweatman B.C., Salman S.R., Farrant R.D., Rahr E., Beddel C.R., Lindon J.C. Automatic reduction of NMR spectroscopic data for statistical and pattern recognition classification of samples. J.Pharm. Biomed. Anal. 1994, 12:1215-1225.
33. Stathopoulou A., Vlachonikolis I., Mavroudis D., Perraki M., Kouroussis C., Apostolaki S., Malamos N., Kakolyris S., Kotsakis A., Xenidis N., Reppa D., Georgoulias V. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J.Clin. Oncol. 2002, 20:3404-3412.
34. Strobl C., Malley J., Tutz G. An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forests. Psychol. Methods 2009, 14:323-348.
35. Urbanczyk-Wochniak E., Willmitzer L., Fernie A.R. Integrating profiling data: using linear correlation to reveal coregulation of transcript and metabolites. Methods Mol. Biol. 2007, 358:77-85.
36. Xenidis N., Vlachonikolis I., Mavroudis D., Perraki M., Stathopoulou A., Malamos N., Kouroussis C., Kakolyris S., Apostolaki S., Vardakis N., Lianidou E., Georgoulias V. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann. Oncol. 2003, 14:849-855.